((自动化翻译由路透提供，请见免责声明 ))
1月10日 - ** 药物开发商 Mersana Therapeutics 股价盘前上涨 5.38% 至 1.38 美元
** 该公司称美国 FDA 已授予其实验药物 XMT-1660 额外的快速通道标签
** 新标签用于治疗某种乳腺癌患者
** FDA的快速通道计划旨在促进候选药物的开发并加快对候选药物的审查，以治疗严重疾病并满足未得到满足的医疗需求。
** 另外，Co 公司还公布了 (link) 在一种乳腺癌患者中进行的早期试验数据。
** 去年股价下跌了 38.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.